Return to homepagePandemic Pact

COVID supplement: Tetramer Research & Development

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93020D00005-0-759302200001-2

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020.0
    2027.0

  • Known Financial Commitments (USD)

    $200,000

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    . JOHN ALTMAN

  • Research Location

    United States of America

  • Lead Research Institution

    EMORY UNIVERSITY

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Not applicable

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The NIH Tetramer Core Facility provides valuable resources to the research community that enable cutting edge research in basic immunology (such as SARS-CoV-2) and a wide variety of infectious disease areas via production and distribution of class I, class II and CD1 reagents. The reagents are being applied to studies of antigen processing and presentation, T cell activation, T cell responses against microbial pathogens or tumors, and T cell-mediated exacerbation or amelioration of immune-mediated diseases. This contract conducts research and development that would enhance the quality, functionality (e.g., sensitivity), and breadth of available tetramer reagents and decrease production time.